Year All20262025202420232022202120202019201820172016 July 13, 2026 Apollomics Regains Full Compliance with Nasdaq Listing Requirements June 24, 2026 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia April 27, 2026 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
June 24, 2026 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
April 27, 2026 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress